Zura Bio (NASDAQ:ZURA) Raised to “Hold” at Wall Street Zen

Zura Bio (NASDAQ:ZURA) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

ZURA has been the subject of a number of other reports. Chardan Capital restated a “buy” rating and issued a $10.00 price objective on shares of Zura Bio in a report on Tuesday, September 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research report on Tuesday, October 14th. HC Wainwright cut their price target on shares of Zura Bio from $3.00 to $2.00 and set a “neutral” rating for the company in a research report on Tuesday, August 19th. Finally, Oppenheimer reduced their price objective on Zura Bio from $17.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, August 15th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.75.

Zura Bio Trading Up 5.5%

ZURA opened at $3.67 on Friday. The stock has a market capitalization of $238.62 million, a P/E ratio of -5.24 and a beta of 0.24. The stock has a 50-day moving average price of $3.08 and a 200-day moving average price of $1.97. Zura Bio has a 12-month low of $0.97 and a 12-month high of $4.85.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02. On average, equities research analysts predict that Zura Bio will post -0.65 EPS for the current year.

Hedge Funds Weigh In On Zura Bio

Several hedge funds and other institutional investors have recently modified their holdings of the company. Savant Capital LLC boosted its holdings in shares of Zura Bio by 190.4% during the second quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after purchasing an additional 21,249 shares during the period. AQR Capital Management LLC bought a new position in Zura Bio during the 1st quarter valued at approximately $72,000. Nuveen LLC purchased a new stake in Zura Bio in the 1st quarter worth approximately $76,000. Forefront Wealth Partners LLC bought a new stake in shares of Zura Bio in the 3rd quarter worth approximately $93,000. Finally, Bank of America Corp DE increased its stake in shares of Zura Bio by 31.9% during the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after buying an additional 9,966 shares during the period. 61.14% of the stock is owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.